Challenges of evaluating the cardiac effects of anticancer agents

[1] BECK J, 2005, P AM SOC CLIN ONC, V23

[2] De Ponti F, 2002, DRUG SAFETY, V25, P263

[3] DUVIC M, 2005, P AM SOC CLIN ONC, V23

[4] Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron [J]. CANCER, 2003, 98 (11) : 2473 - 2482

[5] Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death [J]. HEART, 2006, 92 (03) : 316 - 320

[6] FISCHER T, 2005, P AM SOC CLIN ONC, V23

[7] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron [J]. ANNALS OF ONCOLOGY, 2003, 14 (10) : 1570 - 1577

[8] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) : 3923 - 3931

[9] Kelly WK, 2003, CLIN CANCER RES, V9, P3578

[10] Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer [J]. NATURE REVIEWS CANCER, 2006, 6 (01) : 38 - 51

[1] BECK J, 2005, P AM SOC CLIN ONC, V23

[2] De Ponti F, 2002, DRUG SAFETY, V25, P263

[3] DUVIC M, 2005, P AM SOC CLIN ONC, V23

[4] Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron [J]. CANCER, 2003, 98 (11) : 2473 - 2482

[5] Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death [J]. HEART, 2006, 92 (03) : 316 - 320

[6] FISCHER T, 2005, P AM SOC CLIN ONC, V23

[7] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron [J]. ANNALS OF ONCOLOGY, 2003, 14 (10) : 1570 - 1577

[8] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) : 3923 - 3931

[9] Kelly WK, 2003, CLIN CANCER RES, V9, P3578

[10] Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer [J]. NATURE REVIEWS CANCER, 2006, 6 (01) : 38 - 51